罗特西普治疗骨髓增生异常综合征患者贫血的有效性与安全性的单组率Meta分析

打开文本图片集

中图分类号R979.1 文献标志码A 文章编号 1001-0408（2025）09-1135-06

DOI10.6039/j.issn.1001-0408.2025.09.20

ABSTRACTOBJECTIVETo analyze theeficacyand safetyof luspatercept in the treatment of myelodysplastic syndromes （MDS）anemia，andprovidereferenceforclinicalmedication.METHODSTheliteraturerelatedtoluspaterceptforMDSanemiain PubMed，CochraneLibrary，EmbaseandWebof Science weresearchedbycomputer，and thesearch timewas from the establishmentofthedatabasetoJanuary 2024.Thequalityof literaturewasevaluatedaftertheywerescrenedaccordingto inclusionand exclusioncriteria，thesingle-grouprate meta-analysisandsensitivityanalysis were performedbyusing RevMan5.4 software，andthesubgroupanalysis wasconducted.RESULTSAtotalof756patientsin9articleswereincludedinthisstudyTe results of meta-analysis showed that the proportion of MDS patients who reached ⩾ 8 weeks of red blood cell transfusion independence（RBC-TI）was 4 6 % after using luspatercept [ 9 5 % C ] （0.28，0.64）， P<0 . 0 0 0 01]. The proportion of MDS patients whose hematological improvement in erythrocyte（HI-E）was 5 9 % 二 [ 9 5 % C ] （0.43，0.74）， P<0 . 0 0 0 01].Among them，5articles reported that the proportion of MDS patients with grade 3-4 adverse reactions was 1 4 % [ 9 5 % C ] （0.07，0.22）， P=0 . 0 0 0 2]，and thepoorgeneralcondition，infection，bloodandlymphaticsystemdiseasewerethecommonadversereactions.Subgroupanalysis

showed that the source of heterogeneity was the blood transfusion burden in the proportion of MDS patients with RBC-TI ⩾ 8 weeks，and the source of heterogeneity was the revised international prognostic scoring system （IPSS-R）risk grade，SF3B1 mutation status and blood transfusion burden in

theproportionofMDSpatients with HI-E.Sensitivityanalysis showedthattheresultsofthisstudywere stable.CONCLUSIONS Luspaterceptcansignificantlyimprovebloodtransfusion dependence，reducebloodtransfusion burdenand promotehematology improvement inMDSpatients.Butatentionshouldbepaidtotheoccurrenceof grade3-4adverseevents；adverseeventssuchas poor general condition，infection，blood and lymphatic system diseases are more common.

KEYWORDsluspatercept;myelodysplastic syndromes；anemia;efficacy；safety

骨髓增生异常综合征（myelodysplasticsyndrome，MDS）是一种起源于造血十细胞的异质性髓系肿瘤，其特征包括骨髓发育不良、复发性遗传异常、造血系统发育不良、外周血细胞减少，以及进展为急性髓细胞性白血病（acutemyelogenousleukemia，AML）的高风险[1]。（剩余11201字）